array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2748) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(69) "Ocular Therapeutics Names New Chief Business Officer By Investing.com" ["snippet_en"]=> string(55) "Ocular Therapeutics appoints new chief business officer" ["url"]=> string(63) "https://sa.investing.com/news/company-news/article-93CH-2730740" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2024-11-12" ["categories"]=> array(2) { [0]=> string(10) "Executives" [1]=> string(12) "Board Change" } } [1]=> array(7) { ["title_en"]=> string(95) "Broken String Biosciences Appoints Laurence Reid and Brad Crutchfield to its Board of Directors" ["snippet_en"]=> string(114) "Laurence Reid joins as Chairman, previously Decibel Therapeutics, Warp Drive Bio, Alnylam, and Third Rock Ventures" ["url"]=> string(135) "https://www.biospace.com/press-releases/broken-string-biosciences-appoints-laurence-reid-and-brad-crutchfield-to-its-board-of-directors" ["image_url"]=> string(78) "https://images.businessradar.com/articles/f33d3ddd-22e7-4de2-ab8d-9e7d7ce815b0" ["source"]=> string(12) "biospace.com" ["publication_date"]=> string(10) "2024-09-23" ["categories"]=> array(4) { [0]=> string(20) "Corporate Governance" [1]=> string(12) "Board Change" [2]=> string(18) "Board Compensation" [3]=> string(11) "Acquisition" } } [2]=> array(7) { ["title_en"]=> string(74) "Gianfranco Valenzano becomes Value & Access Director of Astrazeneca Italia" ["snippet_en"]=> string(265) "Starting from October, Gianfranco Valenzano holds the new role of Value & Access Director of AstraZeneca Italia, the local branch of the global biopharmaceutical company, reporting directly to Francesca Patarnello, Vice President Market Access & Government Affairs." ["url"]=> string(118) "https://www.pharmastar.it/news/business/gianfranco-valenzano-diventa-value-access-director-di-astrazeneca-italia-42606" ["image_url"]=> string(78) "https://images.businessradar.com/articles/001b4b5d-bfb4-4f5f-9cf3-1f4f4246cb0c" ["source"]=> string(13) "pharmastar.it" ["publication_date"]=> string(10) "2023-10-27" ["categories"]=> array(4) { [0]=> string(24) "Access and affordability" [1]=> string(10) "Relocation" [2]=> string(12) "Staff hiring" [3]=> string(12) "Board Change" } } [3]=> array(7) { ["title_en"]=> string(35) "REGENERON BOARD GAINS TWO DIRECTORS" ["snippet_en"]=> string(304) "Regeneron Pharmaceuticals Inc. in Tarrytown, New York, recently announced that Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., have joined its Board of Directors. “ Today’ s announcement demonstrates our strong commitment to strategic refreshment of the board, a focus on the recruitment of new" ["url"]=> string(79) "https://westfaironline.com/premium-content/regeneron-board-gains-two-directors/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/9a7df00e-4e3d-4e63-b8b4-1a0fe14e1f28" ["source"]=> string(18) "westfaironline.com" ["publication_date"]=> string(10) "2023-09-18" ["categories"]=> array(1) { [0]=> string(12) "Board Change" } } [4]=> array(7) { ["title_en"]=> string(113) "Phil Vickers talks new role as head of Longwood’s Solu after Faze shutdown; Regeneron CFO to retire in February" ["snippet_en"]=> string(304) "At Solu, two things Vickers emphasizes are the range of the platform and pace to the clinic. “ People in some cases have been trying to develop antibodies for many years against some extracellular portions of proteins,” he said,“ and they’ re just not able to raise therapeutic antibodies against" ["url"]=> string(161) "https://sdbn.org/san-diego-biotech-news/2023/09/15/phil-vickers-talks-new-role-as-head-of-longwoods-solu-after-faze-shutdown-regeneron-cfo-to-retire-in-february/" ["image_url"]=> NULL ["source"]=> string(8) "sdbn.org" ["publication_date"]=> string(10) "2023-09-16" ["categories"]=> array(1) { [0]=> string(12) "Board Change" } } [5]=> array(7) { ["title_en"]=> string(70) "Five things for pharma marketers to know: Thursday, September 14, 2023" ["snippet_en"]=> string(263) "Regeneron deal marks the first time the Biden administration uses its leverage to challenge drugmakers’ list prices; Rocket Pharmaceuticals’ stock surges after aligning with FDA regarding global Phase 2 trial; Former J&J CEO Alex Gorsky joins Neurotech board." ["url"]=> string(116) "https://www.mmm-online.com/home/channel/roundup/five-things-for-pharma-marketers-to-know-thursday-september-14-2023/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/e6092b7d-24d5-46f5-bd9d-eaa21d17ca0f" ["source"]=> string(14) "mmm-online.com" ["publication_date"]=> string(10) "2023-09-13" ["categories"]=> array(2) { [0]=> string(11) "US Politics" [1]=> string(12) "Board Change" } } [6]=> array(7) { ["title_en"]=> string(72) "A tale of two biotechs — 2seventy, Regeneron announce C-suite shakeups" ["snippet_en"]=> string(78) "The biotech’s chief financial officer Robert Landry is retiring in February." ["url"]=> string(98) "https://www.pharmavoice.com/news/Regeneron-CFO-Christopher-Fenimore-Robert-Landry-retiring/693333/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/1ac2d4a5-4aea-4ebd-980e-32fdc27c5f3b" ["source"]=> string(15) "pharmavoice.com" ["publication_date"]=> string(10) "2023-09-12" ["categories"]=> array(3) { [0]=> string(13) "Collaboration" [1]=> string(5) "R & D" [2]=> string(12) "Board Change" } } [7]=> array(7) { ["title_en"]=> string(84) "Regeneron announces CFO transition and board of directors reshuffle By Investing.com" ["snippet_en"]=> string(67) "Regeneron announces CFO transition and board of directors reshuffle" ["url"]=> string(110) "https://in.investing.com/news/regeneron-announces-cfo-transition-and-board-of-directors-reshuffle-93CH-3804982" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2023-09-11" ["categories"]=> array(1) { [0]=> string(12) "Board Change" } } [8]=> array(7) { ["title_en"]=> string(115) "Christopher Fenimore Will Succeed Robert Landry in the role of CFO at Regeneron Pharmaceuticals - CEOWORLD magazine" ["snippet_en"]=> string(272) "Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), the leading biotechnology company, has officially announced that Robert E. Landry, who currently holds the position of Executive Vice President, Finance and Chief Financial Officer of Regeneron, will retire in February 2024." ["url"]=> string(128) "https://ceoworld.biz/2023/09/11/christopher-fenimore-will-succeed-robert-landry-in-the-role-of-cfo-at-regeneron-pharmaceuticals/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/3f68ccec-86ec-4c62-8d9e-5c1737452015" ["source"]=> string(12) "ceoworld.biz" ["publication_date"]=> string(10) "2023-09-11" ["categories"]=> array(1) { [0]=> string(12) "Board Change" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(263) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(201) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(196) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(129) } [4]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(116) } [5]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(116) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(93) } [7]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(79) } [8]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(67) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(66) } [10]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(61) } [11]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(59) } [12]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(57) } [13]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(56) } [14]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(53) } [15]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(43) } [16]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(40) } [17]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(38) } [18]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(37) } [19]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(37) } [20]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(37) } [21]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(35) } [22]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(33) } [23]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(32) } [24]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(31) } [25]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(28) } [26]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(28) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(25) } [28]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(21) } [29]=> array(2) { ["name"]=> string(21) "Intellectual Property" ["count"]=> int(20) } } } c469a-us-regeneron-pharmaceuticals-inc